Entity

Time filter

Source Type

South San Francisco, CA, United States

Patent
Oxigene and Baylor University | Date: 2013-03-05

This invention is directed to compound of Formula I and methods of using these compounds in the treatment of conditions in which modulation of a cathepsin, particularly cathepsin K or cathepsin L, will be therapeutically useful.


Patent
Oxigene | Date: 2012-08-17

The present disclosure provides novel ophthalmic formulations for ocular administration comprising a pharmaceutically effective amount of a combretastatin, from 60% to 95% w/w pre-gelatinized starch, from 1% to 10% w/w hydrophilic matrix forming polymer, and from 0.2% to 5% lubricant.


Methods and compositions for the treatment and prevention of posterior capsular opacification are provided. The method comprises administering a therapeutically effective amount of a combretastatin to a subject suffering from or at risk of developing posterior capsule opacification.


Patent
Oxigene and Baylor University | Date: 2014-10-02

This invention is directed to compound of Formula I and methods of using these compounds in the treatment of conditions in which modulation of a cathepsin, particularly cathepsin K or cathepsin L, will be therapeutically useful.


Trademark
Oxigene | Date: 2016-03-14

Pharmaceutical products for oncological use.

Discover hidden collaborations